APA (7th ed.) Citation

K, B., R, J., M, Z., GG, F., C, E., A, J., . . . LM, S. (2021). The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 27(8), 1883. https://doi.org/10.1177/1078155220971751

Chicago Style (17th ed.) Citation

K, Beyerlin, et al. "The Adjuvant Use of Capecitabine for Residual Disease Following Pre-operative Chemotherapy for Breast Cancer: Challenges Applying CREATE-X to a US Population." Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners 27, no. 8 (2021): 1883. https://doi.org/10.1177/1078155220971751.

MLA (9th ed.) Citation

K, Beyerlin, et al. "The Adjuvant Use of Capecitabine for Residual Disease Following Pre-operative Chemotherapy for Breast Cancer: Challenges Applying CREATE-X to a US Population." Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners, vol. 27, no. 8, 2021, p. 1883, https://doi.org/10.1177/1078155220971751.